![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: AKIRIN1 |
Gene summary for AKIRIN1 |
![]() |
Gene information | Species | Human | Gene symbol | AKIRIN1 | Gene ID | 79647 |
Gene name | akirin 1 | |
Gene Alias | C1orf108 | |
Cytomap | 1p34.3 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q9H9L7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79647 | AKIRIN1 | ATC2 | Human | Thyroid | ATC | 7.94e-06 | 5.90e-01 | 0.34 |
79647 | AKIRIN1 | ATC4 | Human | Thyroid | ATC | 2.03e-14 | -5.07e-02 | 0.34 |
79647 | AKIRIN1 | ATC5 | Human | Thyroid | ATC | 6.64e-34 | 9.11e-01 | 0.34 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00605379 | Esophagus | HGIN | muscle tissue development | 76/2587 | 403/18723 | 2.67e-03 | 2.63e-02 | 76 |
GO:00147068 | Esophagus | HGIN | striated muscle tissue development | 72/2587 | 384/18723 | 3.94e-03 | 3.56e-02 | 72 |
GO:006049117 | Esophagus | HGIN | regulation of cell projection assembly | 39/2587 | 188/18723 | 5.61e-03 | 4.57e-02 | 39 |
GO:003109910 | Esophagus | ESCC | regeneration | 122/8552 | 198/18723 | 4.26e-06 | 4.57e-05 | 122 |
GO:003134616 | Esophagus | ESCC | positive regulation of cell projection organization | 201/8552 | 353/18723 | 1.19e-05 | 1.11e-04 | 201 |
GO:006049118 | Esophagus | ESCC | regulation of cell projection assembly | 110/8552 | 188/18723 | 2.60e-04 | 1.58e-03 | 110 |
GO:012003218 | Esophagus | ESCC | regulation of plasma membrane bounded cell projection assembly | 108/8552 | 186/18723 | 4.37e-04 | 2.46e-03 | 108 |
GO:01200347 | Esophagus | ESCC | positive regulation of plasma membrane bounded cell projection assembly | 64/8552 | 105/18723 | 1.15e-03 | 5.70e-03 | 64 |
GO:00454454 | Esophagus | ESCC | myoblast differentiation | 52/8552 | 84/18723 | 1.98e-03 | 8.90e-03 | 52 |
GO:006053716 | Esophagus | ESCC | muscle tissue development | 211/8552 | 403/18723 | 3.84e-03 | 1.56e-02 | 211 |
GO:00330025 | Esophagus | ESCC | muscle cell proliferation | 134/8552 | 248/18723 | 4.80e-03 | 1.86e-02 | 134 |
GO:000268515 | Esophagus | ESCC | regulation of leukocyte migration | 114/8552 | 210/18723 | 7.26e-03 | 2.63e-02 | 114 |
GO:009758116 | Esophagus | ESCC | lamellipodium organization | 53/8552 | 90/18723 | 7.92e-03 | 2.82e-02 | 53 |
GO:190274515 | Esophagus | ESCC | positive regulation of lamellipodium organization | 24/8552 | 37/18723 | 1.46e-02 | 4.74e-02 | 24 |
GO:001470615 | Esophagus | ESCC | striated muscle tissue development | 197/8552 | 384/18723 | 1.46e-02 | 4.74e-02 | 197 |
GO:009758111 | Liver | Cirrhotic | lamellipodium organization | 40/4634 | 90/18723 | 3.48e-05 | 4.26e-04 | 40 |
GO:003109911 | Liver | Cirrhotic | regeneration | 71/4634 | 198/18723 | 3.02e-04 | 2.65e-03 | 71 |
GO:001059211 | Liver | Cirrhotic | positive regulation of lamellipodium assembly | 16/4634 | 29/18723 | 4.36e-04 | 3.55e-03 | 16 |
GO:190274511 | Liver | Cirrhotic | positive regulation of lamellipodium organization | 19/4634 | 37/18723 | 4.39e-04 | 3.57e-03 | 19 |
GO:190274311 | Liver | Cirrhotic | regulation of lamellipodium organization | 25/4634 | 54/18723 | 4.63e-04 | 3.75e-03 | 25 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AKIRIN1 | SNV | Missense_Mutation | c.295N>G | p.Gln99Glu | p.Q99E | Q9H9L7 | protein_coding | tolerated(0.1) | probably_damaging(0.99) | TCGA-E9-A3QA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
AKIRIN1 | SNV | Missense_Mutation | novel | c.469G>A | p.Glu157Lys | p.E157K | Q9H9L7 | protein_coding | deleterious(0.01) | probably_damaging(0.962) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
AKIRIN1 | SNV | Missense_Mutation | rs753878747 | c.458G>A | p.Arg153Gln | p.R153Q | Q9H9L7 | protein_coding | tolerated(0.09) | possibly_damaging(0.811) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
AKIRIN1 | SNV | Missense_Mutation | novel | c.567N>A | p.Ser189Arg | p.S189R | Q9H9L7 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AKIRIN1 | SNV | Missense_Mutation | rs764613354 | c.225A>C | p.Gln75His | p.Q75H | Q9H9L7 | protein_coding | deleterious(0) | possibly_damaging(0.805) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AKIRIN1 | SNV | Missense_Mutation | novel | c.428N>T | p.Arg143Leu | p.R143L | Q9H9L7 | protein_coding | deleterious(0) | possibly_damaging(0.806) | TCGA-QS-A744-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | SD |
AKIRIN1 | SNV | Missense_Mutation | rs781305153 | c.314C>T | p.Ser105Leu | p.S105L | Q9H9L7 | protein_coding | tolerated(0.16) | benign(0.254) | TCGA-FV-A23B-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
AKIRIN1 | SNV | Missense_Mutation | novel | c.256C>A | p.Arg86Ser | p.R86S | Q9H9L7 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-86-7701-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | etoposide | PD |
AKIRIN1 | SNV | Missense_Mutation | c.180N>T | p.Gln60His | p.Q60H | Q9H9L7 | protein_coding | tolerated(0.09) | benign(0.346) | TCGA-33-4532-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |